BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 12568403)

  • 1. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption.
    Xing L; Carlson L; Story B; Tai Z; Keng P; Siebenlist U; Boyce BF
    J Bone Miner Res; 2003 Feb; 18(2):260-9. PubMed ID: 12568403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
    Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
    J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-1 plays an important role in the bone metabolism under physiological conditions.
    Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
    Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
    O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC
    Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis.
    Soysa NS; Alles N; Weih D; Lovas A; Mian AH; Shimokawa H; Yasuda H; Weih F; Jimi E; Ohya K; Aoki K
    J Bone Miner Res; 2010 Apr; 25(4):809-18. PubMed ID: 19839765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
    Kanazawa K; Kudo A
    J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK.
    Mukohyama H; Ransjö M; Taniguchi H; Ohyama T; Lerner UH
    Biochem Biophys Res Commun; 2000 Apr; 271(1):158-63. PubMed ID: 10777696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
    Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N
    Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.